Finding. In post-mortem brains from 12 people with POLG-related mitochondrial epilepsy, the primary visual cortex loses mitochondrial proteins and gains an innate-immune proteome. Microglia in those cases are OXPHOS-poor. Control visual cortex is already richer in OXPHOS and interneuron proteins than frontal cortex — a baseline that helps explain why this disease detonates occipitally.
Why this paper matters
POLG epilepsy is one of the most brutal presentations of mitochondrial disease: explosive, often occipital, super-refractory status epilepticus in children and young adults, followed by extensive neurodegeneration. The usual story is neuron-autonomous energy failure after mtDNA depletion. Smith, Wilson, Elsaid and colleagues keep that frame but add tissue-level immunometabolism.
They compared occipital Brodmann area 17 — the region that clinically lights up first — with frontal Brodmann area 9 in the same brains, against matched controls. Liquid chromatography–mass spectrometry reports a distinct immunometabolic signature that is strongest occipitally: fewer mitochondrial proteins, more innate-immune and inflammatory proteins. That is not a keyword hit. It is a paired regional proteome in the exact cortex that seizes.
What they actually measured
Immunohistochemistry is used as a validation layer, not a fishing expedition. Acute-phase proteins (CRP, osteopontin, serpin A3), myeloid co-receptors (CD14, HLA-DR), the inflammatory glycoprotein YKL40, TNF-alpha, and mitochondrial TSPO are all increased in cell density. Separately, OXPHOS subunits are reduced inside POLG patient microglia. That last point is the mitochondrial punchline: the inflammatory cell is itself bioenergetically injured.
The control comparison is equally important. Unaffected visual cortex is enriched for OXPHOS and interneuron proteins relative to frontal cortex. If a tissue is constitutively more oxidative and more interneuron-dependent, POLG-driven mtDNA failure has more to break, and inhibitory failure has more to unleash. That is a mechanistic hypothesis with a proteomic foothold, not a slogan.
How to read the score
This is high-importance mitochondrial neuropathology: human, disease-defining phenotype, regional design, orthogonal validation. Confidence is high for the descriptive claim (immunometabolic occipital lesion with glial OXPHOS loss). It is not high for causality. End-stage, post-status brains cannot tell us whether inflammation ignited the first seizure or recorded its aftermath. The abstract does not resolve cell-type proteomes beyond microglia staining, and it does not test an anti-inflammatory or immuno-metabolic intervention.
What to do with it
Track this paper if you model mitochondrial epilepsy, glial bioenergetics, or occipital-selective neurodegeneration. Pull the BA17 vs BA9 protein lists when they are posted. Do not advertise TSPO or TNF as therapeutic targets from this brief. The clinical implication is directional: POLG status epilepticus should be researched as a tissue immunometabolic crisis sitting on an OXPHOS-rich visual cortex, not only as a neuronal ATP outage.